



Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio predict the prognosis in patients with type B aortic dissection receiving thoracic endovascular aortic repair

Kaiwen Zhao^{1#}, Jinzhu Niu^{1#}, Hongqiao Zhu^{1#}, Rong Zhao¹, Yudong Sun², Shuangshuang Li¹, Zaiping Jing^{1*}, Jian Zhou^{1,3*}

¹Department of Vascular Surgery, The First Affiliated Hospital of the Navy Medical University, Shanghai, China; ²Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, China; ³Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai, China

Contributions: (I) Conception and design: K Zhao, J Niu; (II) Administrative support: Z Jing, J Niu; (III) Provision of study materials or patients: H Zhu; (IV) Collection and assembly of data: J Niu, R Zhao; (V) Data analysis and interpretation: K Zhao, Y Sun, S Li; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

^{*}These authors contributed equally to this work.

Correspondence to: Jian Zhou, MD, PhD. Department of Vascular Surgery, The First Affiliated Hospital of the Navy Medical University, 168 Changhai Road, Shanghai 200433, China; Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai, China. Email: zhoujian1_3@163.com; Zaiping Jing, MD, PhD. Department of Vascular Surgery, The First Affiliated Hospital of the Navy Medical University, 168 Changhai Road, Shanghai 200433, China. Email: jingzaiping_vasc@163.com.

Background: The triglyceride-glucose (TyG) index and triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) ratio are both reliable surrogate indicators of insulin resistance and have been shown to be valuable in predicting various cardiovascular diseases. However, few studies have explored its association with the prognosis of type B aortic dissection (TBAD) patients receiving thoracic endovascular aortic repair (TEVAR).

Methods: A total of 1,425 consecutive patients who underwent TEVAR were included. Data from 935 patients were analyzed in the study. The endpoint was defined as 30-day and 1-year aortic-related adverse events (ARAEs), all-cause mortality, and major adverse cardiovascular and cerebrovascular events (MACCEs).

Results: There were 935 patients included during a mean follow-up time of 2.8 years. After adjusting for multiple confounding factors, continuous TG/HDL-c [hazard ratio (HR) =1.07; 95% confidence interval (CI): 1.00–1.15; P=0.041] was independently associated with 1-year all-cause mortality. Both a high (Quintile 5: TG/HDL-c ratio ≥ 4.11) (HR =4.84; 95% CI: 1.55–15.13; P=0.007) and low TG/HDL-c ratio (Quintile 1: TG/HDL-c ratio <1.44) (HR =4.67; 95% CI: 1.46–14.94; P=0.001) were still independent risk factors for 1-year all-cause mortality.

Conclusions: Elevated baseline TG/HDL-c ratio and TG/HDL-c ≥ 4.11 were significantly related to a higher risk of 1-year all-cause mortality among TBAD patients undergoing TEVAR. At the same time, the low TG/HDL-c ratio was also independently associated with 1-year all-cause mortality. Special attention should be paid to TBAD patients with a higher or an overly low TG/HDL-c ratio.

Keywords: Type B aortic dissection (TBAD); thoracic endovascular aortic repair (TEVAR); insulin resistance (IR); triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-c ratio); triglyceride-glucose index (TyG index)

Submitted Sep 07, 2023. Accepted for publication Feb 05, 2024. Published online Mar 27, 2024.

doi: 10.21037/jtd-23-1411

View this article at: <https://dx.doi.org/10.21037/jtd-23-1411>

Introduction

Type B aortic dissection (TBAD) is one of the most fatal cardiovascular diseases (CVDs); it is classified as the entry tear distal to the left subclavian artery with sparing of the ascending aorta (1). The incidence of aortic dissection (AD) is the highest in age group of 65 to 75 years, with 35 cases per 100,000 people per year in this population (2). Hypertension, dyslipidemia and genetic disorders are considered as other contributing factors (3). Patients with TBAD are typically treated with medication and thoracic endovascular aortic repair (TEVAR) (4), which has been found to lower the incidence of aortic-related adverse events (ARAEs) and mortality and led to favorable aortic remodeling in TBAD patients (5,6). However, ARAEs such as retrograde type A dissection (RTAD), aortic rupture, aortic dilatation, etc., after TEVAR may undermine its advantage (7). Therefore, it is crucial to have better risk stratification of patients, which is also a challenge for the facilitation of the management of patients with TBAD.

A number of factors including D-dimer, platelets, neutrophil-to-lymphocyte ratio (NLR), etc. have been proposed to be possibly related with the outcomes of TBAD patients who undergo TEVAR (8-10). Our previous study found that peripheral eosinophil count was associated with 1-year all-cause mortality in TBAD patients (11). Additional indicators mediated by novel mechanisms may improve the effectiveness of the current prognostic model for TBAD patients undergoing TEVAR.

Insulin resistance (IR) refers to diminished or impaired reactivity to endogenous and exogenous insulin in the tissues

and organs that are dependent on insulin (12). IR has been proven to be a significant risk factor for the development of CVD and type 2 diabetes mellitus (T2DM) (13). Triglyceride-glucose (TyG) index and triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) ratio were also suggested as straightforward and reliable surrogate indicators of IR as a result of strongly correlating with the euglycemic hyperinsulinemia clamp and are appropriate for clinical use and large epidemiological studies (14,15). TyG index has been found to be positively correlated with coronary heart disease risk and reflect coronary atherosclerosis severity (16). An analysis of UK Biobank data also revealed that TyG index and TG/HDL-c ratio were potential CVD risk factors (17).

However, very few studies focused on the influence of the TG/HDL-c ratio and TyG index on the prognosis of TBAD patients who undergo TEVAR. Consequently, our study aims to explore the effect of the baseline TG/HDL-c ratio and TyG index on 30-day and 1-year outcomes in TBAD patients. We present this article in accordance with the TRIPOD reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1411/rc>).

Methods

Study cohort and design

This is a retrospective cohort study. From January 2005 to June 2021, a total of 1,425 consecutive TBAD patients underwent TEVAR at The First Affiliated Hospital of the Navy Medical University, Shanghai, China. The exclusion criteria included: (I) traumatic AD; (II) Marfan syndrome, Turner's syndrome, bicuspid aortic valve, Bechet's disease, Ehlers-Danlos syndrome, giant cell arteritis, ankylosing spondylitis, or Takayasu arteritis; (III) previous aortic surgery; (IV) suspected familial hypertriglyceridemia (plasma TGs ≥ 500 mg/dL); (V) a history of malignancy; (VI) and missing admission glucose or TG measurement (*Figure 1*). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The research protocol was approved by The First Affiliated Hospital of the Navy Medical University central ethics committee (CHEC-Y2021, March 1, 2021). Informed consent was waived due to the retrospective nature of the study.

Data collection and definitions

The electronic medical records were used to gather

Highlight box

Key findings

- The triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) ratio is significantly related to the risk of 1-year all-cause mortality among type B aortic dissection (TBAD) patients undergoing thoracic endovascular aortic repair (TEVAR).

What is known and what is new?

- Continuous TG/HDL-c ratio and a higher or an overly low TG/HDL-c ratio are independent risk factors for 1-year all-cause mortality.
- Insulin resistance, represented by TG/HDL-c ratio, may be a novel mechanism influencing aortic remodeling after TEVAR.

What is the implication, and what should change now?

- The evaluation of TG/HDL-c ratio before TEVAR is necessary for TBAD patients for additional risk stratification, refined management and postoperative monitoring.




Figure 1 Flowchart of the patient selection process. MACCEs, major adverse cardiovascular and cerebrovascular events; TG/HDL-c, triglyceride to high-density lipoprotein cholesterol.

information on sociodemographic characteristics, medical history, smoking status, comorbidities, laboratory testing, and intra-operative details. The imaging department provided the image information. TBAD was classified as an AD with an entry tear in zone 3 or 4 (18). AD was categorized as acute (1–14 days), subacute (15–90 days), and chronic (>90 days) according to Society for Vascular Surgery (SVS)/Society of Thoracic Surgeons (STS) recommendations (18). ARAEs included aortic rupture, malperfusion, RTAD, aortic dilation, and type I/III endoleak (7). The blood samples of patients who received surgery that are not performed in urgent/emergency setting were collected at 6 a.m. on the day of surgery. If it was an emergency surgery, the blood samples were obtained in the emergency room or during surgery. Standard biochemical methods were used at the Clinical Laboratory of The First Affiliated Hospital of the Navy Medical University to assess laboratory parameters such as D-dimer, creatinine, glucose, TG, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and uric acid. The following equation was used to construct the TyG index: $\ln [TG \text{ (mg/dL)} \times \text{glucose (mg/dL)} / 2]$ (19). The TG/HDL-c ratio was computed by dividing the TG (mg/dL)

by the HDL-C (mg/dL) levels (17). Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) $<60 \text{ mL/min/1.73 m}^2$.

Follow-up and endpoints

Research was conducted with qualified researchers by phone survey or by reviewing the medical records of all patients. Furthermore, adverse events were assessed in the comprehensive clinical files of patients requiring re-admission or reviewed in clinic. Study endpoints included the following 30-day outcomes: 30-day all-cause death; 30-day stroke and 1-year outcomes: 1-year all-cause death and 1-year major adverse cardiovascular and cerebrovascular events (MACCEs). ARAEs, which were traditionally believed to be only associated with technical failure, were also depicted in this study. Two clinicians experienced in the diagnosis and treatment of TBAD blindly evaluated the adverse events and patients' outcome.

Statistical analysis

The participants were classified into five groups [Quintile

1 (Q1) (n=186, TG/HDL-c ratio <1.44), Quintile 2 (Q2) (n=187, 1.44 ≤ TG/HDL-c ratio <2.09), Quintile 3 (Q3) (n=188, 2.09 ≤ TG/HDL-c ratio <2.97), Quintile 4 (Q4) (n=186, 2.97 ≤ TG/HDL-c ratio <4.11), and Quintile 5 (Q5) (n=188, TG/HDL-c ratio ≥4.11), by the quintiles of TG/HDL-c ratio, and the Q4 group was used as the reference group, and the characteristics were depicted. Variables with continuous distributions were compared using a student *t*-test or Mann-Whitney test based on the means, standard deviations or medians (quintiles 1 through 5). Categorical variables were reported as percentages and tested with Chi-squared or Fisher's exact tests. TG/HDL-c ratio was originally input as a continuous variable and then modeled as a categorical variable. We calculated cumulative survival curves using Kaplan-Meier (KM) methods and used log-rank tests to differentiate between groups.

Univariable and multivariable Cox regression models for 1-year all-cause mortality, as well as Cox regression models for 1-year ARAEs, were applied to investigate the relationship between the preoperative TG/HDL-c ratio and 1-year outcomes. Variables with a P value of 0.1 in the univariable analysis were introduced into the multivariable models using a stepwise forward approach. Moreover, we employed general additive models (GAMs) with restricted cubic splines (RCS) (giving 4 degrees of freedom) for visual analysis to evaluate the nonlinear correlations between continuous variables and outcomes. The statistical analyses were performed using R version 3.6.3 and EmpowerStats software (www.empowerstats.com). A P value of 0.05 was chosen as the statistical significance level.

Results

Clinical characteristics

Table 1 demonstrates the participant characteristics both overall and stratified by the quintiles of the TG/HDL-c ratio. The mean age of the included 935 patients was 59.8±13.3 years, with 759 (81.2%) men (P=0.001). Q1 group was significantly older in the all groups (P<0.001). Smoking history and sex were statistically different among the groups (P=0.001). The body mass index (BMI) of the five quintiles were 23.5±3.7, 24.0±3.9, 24.4±3.3, 24.9±3.1, and 25.4±3.7 kg/m², respectively, which was significantly different (P<0.001). Systolic blood pressure (SBP), and diastolic blood pressure (DBP) did not differ significantly among the groups (all P>0.05). There was no significant difference in comorbidities among groups (all P>0.05).

In terms of laboratory tests, the difference in platelet (P=0.002), creatinine (P=0.012), total cholesterol (P<0.001) and LDL-C (P=0.028) was statistically significant among groups. The uric acid was remarkably higher in Q5 group (231.9±2,323.6 mg/dL, P<0.001) compared with the other groups. The difference in other laboratory tests [white blood cell (WBC), hemoglobin, D-dimer and glucose] was not significant (all P>0.05). Branch, adjunct, and hybrid technique utilization and the timing of TEVAR among groups were not statistically different (all P>0.05). Besides, the anatomical characteristics of the five groups were comparable (all P>0.05) except for the extent of proximal thrombosis of the false lumen (P<0.001).

30-day outcomes

The average length of stay in the hospital following TEVAR was 11.8±6.6 days in the Q1 group, 12.4±7.4 days in the Q2 group, 11.4±6.2 days in the Q3 group, 11.2±5.7 days in the Q4 group, and 12.8±9.5 days in the Q5 group (P=0.129). In hospitalization or 30 days after TEVAR, there were no significant differences in mortality among the five groups (3.2% vs. 1.1% vs. 1.6% vs. 1.1% vs. 2.7%, P=0.441). There was also no statistical difference in the 30-day stroke after TEVAR (1.1% vs. 0.5% vs. 0.0% vs. 0.5% vs. 1.6%, P=0.444). The 30-day outcomes are detailed in Table 2.

1-year outcomes

The cumulative incidence rates for 1-year all-cause mortality and MACCEs are reported in Table 2. A total of 20 MACCEs and 46 fatalities were found during the 1-year follow-up. There was no significant difference in the cumulative incidence of 1-year all cause death (8.54% vs. 4.01% vs. 4.87% vs. 2.71% vs. 9.16%, P=0.052) and 1-year MACCEs (1.89% vs. 4.82% vs. 1.53% vs. 1.51% vs. 3.62%, P=0.264) among the five groups (Table 2). However, there were significant difference in the 1-year all-cause mortality between Q4 and Q1 (P=0.02), as well as Q4 and Q5 (P=0.02) (Figure 2).

Table 3 reveals the findings of the Cox proportional hazard modeling evaluation. Multivariable Cox regression analysis indicated that TG/HDL-c ratio (modeled as a continuous variable) was strongly linked with 1-year all cause death [hazard ratio (HR) =1.07; 95% confidence interval (CI): 1.00–1.15; P=0.041] (Table 3, Table S1). Other independent predictors for 1-year all-cause mortality included stroke (HR =2.64; 95% CI: 1.09–6.41; P=0.031), CKD (HR =2.71; 95% CI: 1.08–6.82; P=0.034),

Table 1 Baseline characteristics of TBAD patients according to quintile of the TG/HDL-c index

Variables	Total	TG/HDL-c					P value
		Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5	
N	935	186	187	188	186	188	–
Age (years)	59.8±13.3	62.7±14.0	60.3±13.3	60.7±12.7	59.8±13.2	55.6±12.1	<0.001
Male	759 (81.2)	140 (75.3)	142 (75.9)	151 (80.3)	158 (84.9)	168 (89.4)	0.001
BMI (kg/m ²)	24.4±3.6	23.5±3.7	24.0±3.9	24.4±3.3	24.9±3.1	25.4±3.7	<0.001
Smoking	475 (50.8)	72 (38.7)	90 (48.1)	99 (52.7)	108 (58.1)	106 (56.4)	0.001
SBP at admission (mmHg)	137.3±21.8	139.9±24.0	137.6±22.0	136.1±20.3	135.9±22.2	137.3±20.6	0.415
DBP at admission (mmHg)	81.7±11.6	82.2±11.9	80.7±12.1	81.5±11.0	81.3±11.3	82.6±11.4	0.538
Comorbidities							
Hypertension	705 (75.4)	134 (72.0)	137 (73.3)	140 (74.5)	149 (80.1)	145 (77.1)	0.379
Diabetes mellitus	87 (9.3)	9 (4.8)	17 (9.1)	17 (9.0)	23 (12.4)	21 (11.2)	0.123
Stroke	57 (6.1)	7 (3.8)	11 (5.9)	14 (7.4)	17 (9.1)	8 (4.3)	0.164
CAD	60 (6.4)	12 (6.5)	7 (3.7)	9 (4.8)	18 (9.7)	14 (7.4)	0.154
COPD	124 (13.3)	28 (15.1)	24 (12.8)	30 (16.0)	27 (14.5)	15 (8.0)	0.162
CKD	56 (6.0)	15 (8.1)	6 (3.2)	10 (5.3)	16 (8.6)	9 (4.8)	0.142
Pericardial effusion	69 (7.4)	19 (10.2)	12 (6.4)	19 (10.1)	9 (4.8)	10 (5.3)	0.116
Pleural effusion	316 (33.8)	67 (36.0)	72 (38.5)	61 (32.4)	66 (35.5)	50 (26.6)	0.135
Laboratory tests							
WBC (×10 ⁹ /L)	8.6±3.6	8.6±3.6	8.9±4.1	8.1±3.0	8.4±3.7	8.9±3.7	0.167
Platelet (×10 ⁹ /L)	210.6±87.6	183.8±76.1	220.1±86.5	210.1±97.2	218.8±83.3	218.3±88.3	0.002
Hemoglobin (g/L)	128.0±19.9	125.4±21.0	128.0±17.3	127.3±20.2	129.1±19.7	130.0±21.2	0.288
D-dimer (mg/L)	3.4±4.6	4.0±6.1	3.5±4.2	3.1±3.8	2.9±3.7	3.5±4.8	0.346
Creatinine (μmol/L)	103.4±111.7	114.0±140.2	90.7±62.9	99.9±92.2	112.8±139.3	100.9±108.0	0.012
Glucose (mg/dL)	120.7±41.3	116.4±33.0	124.6±44.4	115.4±35.7	122.3±48.7	124.6±42.0	0.065
Total cholesterol (mg/dL)	170.9±42.7	162.1±36.4	168.7±35.4	167.9±35.4	174.4±38.6	181.2±60.2	<0.001
Triglycerides (mg/dL)	123.7±85.7	58.7±16.7	86.0±18.4	107.4±22.3	136.2±31.6	229.4±131.5	<0.001
LDL-C (mg/dL)	53.9±179.3	29.5±58.4	41.4±116.1	38.8±34.1	80.4±269.7	78.9±262.4	0.028
HDL-C (mg/dL)	44.7±13.7	58.9±15.8	49.0±9.9	43.2±8.4	39.0±8.3	33.3±8.8	<0.001
Uric acid (mg/dL)	89.6±1045.1	50.2±16.7	51.9±17.0	56.7±20.6	55.2±20.3	231.9±2,323.6	<0.001
Intra-operative details							
Timing of operation							0.03
Acute	537 (57.4)	113 (60.8)	119 (63.6)	105 (55.9)	114 (61.3)	86 (45.7)	
Sub-acute	285 (30.5)	50 (26.9)	49 (26.2)	58 (30.9)	55 (29.6)	71 (37.8)	
Chronic	113 (12.1)	23 (12.4)	19 (10.2)	25 (13.3)	17 (9.1)	31 (16.5)	
Branch	153 (16.4)	29 (15.6)	34 (18.2)	27 (14.4)	29 (15.6)	34 (18.1)	0.814
Adjunct	135 (14.4)	18 (9.7)	35 (18.7)	27 (14.4)	27 (14.5)	28 (14.9)	0.184
Hybrid	10 (1.1)	2 (1.1)	2 (1.1)	1 (0.5)	3 (1.6)	2 (1.1)	0.905

Table 1 (continued)

Table 1 (continued)

Variables	Total	TG/HDL-c					P value
		Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5	
Anatomical characteristics							
Dissection length (mm)	419.7±135.9	379.2±110.3	451.4±105.9	411.0±159.7	383.8±174.3	456.1±120.8	0.175
Proximal thrombosis of FL							<0.001
Patent	387 (41.4)	66 (35.5)	70 (37.4)	77 (41.0)	97 (52.2)	76 (40.4)	
Partial	298 (31.9)	71 (38.2)	77 (41.2)	60 (31.9)	35 (18.8)	56 (29.8)	
Complete	146 (15.6)	32 (17.2)	24 (12.8)	28 (14.9)	25 (13.4)	36 (19.1)	
ULP	104 (11.1)	17 (9.1)	16 (8.6)	23 (12.2)	29 (15.6)	20 (10.6)	
Superior mesenteric arteries	5 (0.5)	0 (0.0)	1 (0.5)	1 (0.5)	2 (1.1)	1 (0.5)	0.732
Renal arteries	33 (3.5)	4 (2.2)	10 (5.3)	8 (4.3)	4 (2.2)	7 (3.7)	0.379
Common hepatic arteries	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.5)	0 (0.0)	0.402
Lower-extremity arteries	9 (1.0)	0 (0.0)	3 (1.6)	0 (0.0)	4 (2.2)	2 (1.1)	0.125

Values are presented as n (%) or mean ± standard deviation. Quintile 1: TG/HDL-c ratio <1.44. Quintile 2: 1.44 ≤ TG/HDL-c ratio <2.09. Quintile 3: 2.09 ≤ TG/HDL-c ratio <2.97. Quintile 4: 2.97 ≤ TG/HDL-c ratio <4.11. Quintile 5: TG/HDL-c ratio ≥4.11. TBAD, type B aortic dissection; TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; WBC, white blood cell; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FL, false lumen; ULP, ulcer-like projection.

Table 2 30-day and 1-year outcomes of TBAD patients receiving TEVAR according to quintiles of the TG/HDL-c index

Variables	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5	P value
Hospital stays of post-TEVAR (days)	11.8±6.6	12.4±7.4	11.4±6.2	11.2±5.7	12.8±9.5	0.129
30-day outcomes						
30-day mortality	6 (3.2)	2 (1.1)	3 (1.6)	2 (1.1)	5 (2.7)	0.441
30-day stroke	2 (1.1)	1 (0.5)	0 (0.0)	1 (0.5)	3 (1.6)	0.444
1-year outcomes						
Cumulative incidence of 1-year all cause death (%)	8.54 [3.91–12.95]	4.01 [0.78–7.13]	4.87 [1.5–8.13]	2.71 [0–5.34]	9.16 [4.6–13.5]	0.052
Cumulative incidence of MACCEs (%)	1.89 [0–4]	4.82 [1.26–8.27]	1.53 [0–3.62]	1.51 [0–3.59]	3.62 [0.72–6.4]	0.264

Values are presented as n (%), mean ± standard deviation or mean [95% CI]. Quintile 1: TG/HDL-c ratio <1.44. Quintile 2: 1.44 ≤ TG/HDL-c ratio <2.09. Quintile 3: 2.09 ≤ TG/HDL-c ratio <2.97. Quintile 4: 2.97 ≤ TG/HDL-c ratio <4.11. Quintile 5: TG/HDL-c ratio ≥4.11. TBAD, type B aortic dissection; TEVAR, thoracic endovascular aortic repair; TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; MACCEs, major adverse cardiovascular and cerebrovascular events; CI, confidence interval.

and pericardial effusion (HR =0.69; 95% CI: 1.55–8.80; P=0.003) (Table S1). As a categorical variable, patients with TG/HDL-c ratio <1.44 (HR =4.67; 95% CI: 1.46–14.94; P=0.001) and TG/HDL-c ratio ≥4.11 (HR =4.84; 95% CI: 1.55–15.13; P=0.007) had higher risk of 1-year all-cause mortality (Table 3, Table S2). However, continuous TyG index was not found to be related to 1-year all-cause death

and 1-year MACCEs (all P>0.05) (Table S3).

Additionally, we performed subgroup analyses to investigate the impacts of various potential confounding factors, including smoking history, gender, age, SBP, DBP, high blood pressure (HBP), coronary artery disease (CAD), diabetes mellitus, stroke, chronic obstructive pulmonary disease (COPD), CKD and timing of operation (Figure




Figure 2 Kaplan-Meier survival analysis of 1-year outcomes for TBAD patients undergoing TEVAR. (A) The 1-year overall survival probability. (B) The 1-year freedom from MACCEs. Quintile 1: TG/HDL-c ratio <1.44. Quintile 2: $1.44 \leq$ TG/HDL-c ratio <2.09. Quintile 3: $2.09 \leq$ TG/HDL-c ratio <2.97. Quintile 4: $2.97 \leq$ TG/HDL-c ratio <4.11. Quintile 5: TG/HDL-c ratio ≥ 4.11 . MACCEs, major adverse cardiovascular and cerebrovascular events; TBAD, type B aortic dissection; TEVAR, thoracic endovascular aortic repair; TG/HDL-c, triglyceride to high-density lipoprotein cholesterol.

Table 3 Association of TyG index and TG/HDL-c ratio on 1-year all-cause death and MACCEs

Variables	Univariate Cox regression model				Multivariate Cox regression model	
	1-year all-cause death	P value	1-year MACCEs	P value	1-year all-cause death	P value
Continuous TG/HDL-c	1.07 (1.01, 1.13)	0.030	1.05 (0.95, 1.17)	0.341	1.07 (1.00, 1.15)	0.041
Continuous TyG index	1.32 (0.84, 2.09)	0.225	1.37 (0.69, 2.72)	0.365	NA	NA
TG/HDL-c ratio groups						
Quintile 4	Reference		Reference		Reference	
Quintile 1	3.42 (1.12, 10.50)	0.031	1.61 (0.27, 9.63)	0.602	4.67 (1.46, 14.94)	0.001
Quintile 2	1.47 (0.41, 5.21)	0.551	3.46 (0.72, 16.66)	0.122	1.88 (0.52, 6.82)	0.337
Quintile 3	1.94 (0.58, 6.44)	0.280	0.98 (0.14, 6.94)	0.982	2.21 (0.65, 7.57)	0.206
Quintile 5	3.55 (1.18, 10.69)	0.024	2.91 (0.59, 14.44)	0.190	4.84 (1.55, 15.13)	0.007

Values are presented as HR (95% CI). Covariates for the multivariable model include age, gender, body mass index, smoking, systolic blood pressure, diastolic blood pressure, hypertension, diabetes, stroke, chronic obstructive pulmonary disease, chronic kidney disease, coronary artery disease, timing of operation, pericardial effusion, pleura effusion, white blood cell counts, platelet, creatinine, LDL-C, HDL-C, uric acid. Variables with a P value <0.1 in univariable analysis were entered in the multivariable models (details in the [Tables S1-S4](#)). Quintile 1: TG/HDL-c ratio <1.44. Quintile 2: $1.44 \leq$ TG/HDL-c ratio <2.09. Quintile 3: $2.09 \leq$ TG/HDL-c ratio <2.97. Quintile 4: $2.97 \leq$ TG/HDL-c ratio <4.11. Quintile 5: TG/HDL-c ratio ≥ 4.11 . TyG, triglyceride-glucose; TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; MACCEs, major adverse cardiovascular and cerebrovascular events; NA, not applicable; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval.

3). There was no interaction in the all subgroups (all P for interaction >0.05). Moreover, neither TG/HDL-c nor TyG index were found to be related to 1-year MACCEs in the univariate Cox proportional hazard modeling ([Table 3](#)); the details are presented in [Table S4](#).

The RCS identified non-linear relationships between TG/HDL-c, TyG index and 1-year outcomes ([Figure 4](#)). Unexpectedly, there seemed to be a U-shaped correlation between TG/HDL-c and 1-year all-cause outcomes. The log relative risk (RR) for 1-year all-cause mortality was




Figure 3 Subgroup analysis for association between TG/HDL-c and 1-year outcomes. HR, hazard ratio; CI, confidence interval; TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.

higher when the TG/HDL-c ratio was below 2.72 and when it was above 2.72. There were no obvious associations between TyG and 1-year MACCEs, nor between TG/HDL-c and 1-year MACCEs.

A discriminant analysis (Wilks' Lambda) was also performed to investigate the potential influences of 1-year ARAEs (Tables S5,S6).

Discussion

IR is a systemic condition that affects insulin-regulated

pathways and multiple organs and is characterized by diminished tissue sensitivity or reaction to circulating insulin, which may be related to obesity, genetic abnormalities, or anti-insulin receptor (20,21). Euglycemic clamp is the gold standard for measuring IR; however, due to the sophisticated procedures, it is not ideal to utilize it as a routine screening item for admission and inappropriate for large-scale investigations (22). Previous studies have shown that TyG index and TG/HDL-c ratio are simple and reliable surrogate markers for IR, that are applicable to both clinical practice and large epidemiological studies (23,24).




Figure 4 The association between TG/HDL-c and 1-year outcomes and the association between TyG index and 1-year outcomes. (A) The relationship between TG/HDL-c and log RR for 1-year mortality. (B) The relationship between TG/HDL-c and log RR for 1-year MACCEs. (C) The relationship between TyG index and log RR for 1-year mortality. (D) The relationship between TyG index and log RR for 1-year MACCEs. TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; MACCEs, major adverse cardiovascular and cerebrovascular events; TyG, triglyceride-glucose; RR, relative risk.

It has been shown that TG/HDL-c ratio and TyG index were associated with adverse cardiovascular events such as acute coronary syndrome, chronic coronary syndrome, myocardial infarction, ischemic stroke, and cardiac death (17,25). The study has been designed specifically to analyse a potential relationship between TG/HDL-c ratio and the 1-year prognosis of TBAD patients undergoing TEVAR, which may have a role to play in the management of the residual disease. We found a strong association between the TG/HDL-c ratio and 1-year all-cause mortality. The independent association remained statistically significant after adjustment for the well-established AD risk factors and

potential confounding risk factors.

The impact of the TG/HDL-c ratio on the outcomes of TBAD patients may be mediated by inflammation. AD is recognized as an inflammatory-related vascular disease (26,27). Local neutrophils recruitment and activation has been observed to trigger aortic rupture while disruption of IL-6 significantly decreases dilatation of the dissected aorta (28). Inflammatory factors may influence the progression and outcome of AD patients. A previous study found that perioperative NLR and systemic inflammatory response index were associated with re-intervention and 1-year outcomes of TBAD patients

(29,30). IR is a prominent comorbidity of obesity, arising from a combination of fat excess-triggered abnormalities, including lipotoxicity and meta-inflammation (31). Perry *et al.* revealed a critical role for inflammation as a divulged etiology for IR (32). Patients with IR may have higher levels of inflammatory cytokine release, leading to adverse events of TBAD patients. Besides, a study found that mitophagy-mediated adipose inflammation leads to type 2 diabetes with hepatic IR (33). Perivascular adipose tissue (PVAT) has been reported to undergo inflammatory changes in response to vascular injury (34). Adachi *et al.* showed that the beiging (brown adipose tissue-like phenotype change) of PVAT fine-tunes inflammatory response and thus regulates the vascular remodeling (35). PVAT density, which measures vessel inflammation, has been found to be independently associated with the progression of coronary atherosclerosis (36). TG/HDL-c ratio has been used to predict outcomes of numerous cardiovascular inflammatory disorders (37,38).

In addition, IR may have a profound effect on aortic structural cells. The progression of thoracic AD is directly correlated with the breakdown of extracellular matrix and the switch from contractile to synthetic vascular smooth muscle cells (VSMCs) (39). Zheng *et al.* found that IR promotes the formation of AD by inducing the phenotypic switch of VSMCs (40). Except for VSMCs in the media, endothelial cells are a key component of the intima of the aorta. It has been recently shown that the disruption of endothelial tight junctions' function is an early event prior to TAAD formation (41). Insulin stimulates the phosphatidylinositol 3-kinase pathway, resulting in endothelial nitric oxide generation and vasodilation, while IR compromises this pathway and leads to vascular dysfunction (42). According to the available research, IR is a secondary cause of progressive endothelial dysfunction, disorders of glucolipid metabolism, vascular damage brought on by lipid deposition and oxidative stress in the vascular wall, an inflammatory response, and the release of chemoattractants and cytokines, which worsen IR and endothelial dysfunction (43).

Other factors may underpin the potential association between the TG/HDL-c ratio and prognosis of TBAD patients. The indicator is not closely related to various comorbidities, including hypertension, diabetes mellitus, stroke, etc. It has been reported that dyslipidemia, diabetes mellitus, and hypertension explained 45.8%, 27.0%, and 15.0% of TyG index's association with CVD in mediation analyses, respectively (17). However, after adjustment of

the confounding factors in the multivariate Cox analyses, TG/HDL-c ratio is still independent risk factor for 1-year outcomes (Table 3). In stratified analysis (Figure 3), we discovered that the covariates did not substantially modify the correlation of TG/HDL-c ratio with the prognosis of TBAD patients treated with TEVAR, suggesting that the results of this study are relevant to most of the general population. Furthermore, Tripolino *et al.* revealed that a high TyG index is associated with increased wall shear stress in the common carotid artery, which may explain the higher risk of 1-year aortic dilation after TEVAR (44).

Moreover, we discovered a fascinating phenomenon in our study: the relationship between TG/HDL-c ratio and 1-year prognosis showed a slight U-shaped relationship. A lower TG/HDL-c ratio also led to an increased risk of adverse events and mortality. According to a cohort study, people with CAD have a paradoxically increased mortality risk when their HDL-C levels are quite high (45). It has also been indicated that men and women in the general population with extremely high HDL-C paradoxically have high all-cause mortality (46). This may be an important reason for the association between low TG/HDL-c ratio and poor prognosis.

Overall, our findings reinforce the predictive value of TG/HDL-c ratio, which may represent new mechanisms affecting the prognosis of patients with TBAD. Compared with other detection methods, TG/HDL-c ratio detection is simple, rapid and reproducible, and they are an ideal clinical monitoring index that has high clinical relevance for preoperative evaluation, postoperative monitoring and prevention of complications. Implementing the TG/HDL-c ratio into routine clinical assessments requires more standardized protocols for measuring fasting triglyceride and glucose levels. Establishing threshold values indicating increased risk and developing guidelines for clinical decision-making based on these values would be essential. Large-scale prospective studies are needed to confirm its reliability and reproducibility across diverse patient populations. Patients with a higher TG/HDL-c ratio than the threshold might be considered for more intensive monitoring post-TEVAR or could receive more aggressive management of cardiovascular risk factors, such as stricter blood pressure control and the utilization of antihypertensive drugs. Follow-up criteria for TBAD patients who have undergone TEVAR includes regular imaging studies, which are essential to evaluate the aortic repair site; regular clinical examinations to assess symptoms, including chest or back pain, signs of organ

malperfusion; strict blood pressure control that is vital in preventing aortic expansion and reducing the risk of further dissection or rupture; periodic blood tests which can help assess renal function, monitor for end-organ damage, and evaluate metabolic parameters; medication adherence that ensure patients are compliant with prescribed medications, including antihypertensives, antiplatelet agents, or anticoagulants, if indicated.

Finally, TyG index and the TG/HDL-c ratio, representing the IR mechanism which is often neglected in the treatment of TBAD patients, may be used to improve the precision of traditional predication models. Combination indexes, such as TyG-platelets index, may also be made by integrating the TyG index and other traditional risk factors such as NLR, platelets, and D-dimer etc.

Limitations

This study has several limitations. (I) This study was a retrospective study. Data records for certain patients may be inaccurate, resulting in increased margins of error. (II) The role of TG/HDL-c ratio and TyG index in the diagnosis of TBAD needs further study, including in combination with other biomarkers. (III) The study was not originally planned for the TG/HDL-c ratio and TyG index, but is a retrospective assessment of computer-collected data, including the TyG index.

Conclusions

The findings of this study indicated that continuous TG/HDL-c ratio, TG/HDL-c ratio <1.44 , and TG/HDL-c ratio ≥ 4.11 were independent risk factors related to increased risks of 1-year all-cause death for TBAD patients receiving TEVAR. Special attention should be paid to TBAD patients with continuous TG/HDL-c and too low or too high TG/HDL-c ratio.

Acknowledgments

The authors thank all members of the Department of Vascular Surgery at The First Affiliated Hospital of the Navy Medical University, Shanghai, China, for their assistance in the data investigation.

Funding: The study, and collection, analysis, interpretation of data, and preparation of the manuscript were supported by the source of funding as follows: the National Natural Science Foundation of China (Nos. 82270513, 82170500,

and 82000464) and National Innovation Talent Promotion Plan (No. 2019RA2132).

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1411/rc>

Data Sharing Statement: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1411/dss>

Peer Review File: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1411/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-1411/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The research protocol was approved by The First Affiliated Hospital of the Navy Medical University central ethics committee (CHEC-Y2021, March 1, 2021). Informed consent was waived due to the retrospective nature of the study.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Lombardi JV, Hughes GC, Appoo JJ, et al. Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) reporting standards for type B aortic dissections. *J Vasc Surg* 2020;71:723-47.
2. Nienaber CA, Clough RE, Sakalihasan N, et al. Aortic

- dissection. *Nat Rev Dis Primers* 2016;2:16053.
3. Evangelista A, Isselbacher EM, Bossone E, et al. Insights From the International Registry of Acute Aortic Dissection: A 20-Year Experience of Collaborative Clinical Research. *Circulation* 2018;137:1846-60.
 4. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2014;35:2873-926.
 5. Qin YL, Wang F, Li TX, et al. Endovascular Repair Compared With Medical Management of Patients With Uncomplicated Type B Acute Aortic Dissection. *J Am Coll Cardiol* 2016;67:2835-42.
 6. Ahmad W, Brunkwall J, Bunck AC, et al. Favorable Remodeling After TEVAR in Uncomplicated Acute and Subacute Type B Aortic Dissection in Comparison to Conservative Treatment: A Midterm Analysis. *J Endovasc Ther* 2023. [Epub ahead of print]. doi: 10.1177/15266028231158971.
 7. Zhang L, Zhao Z, Chen Y, et al. Reintervention after endovascular repair for aortic dissection: A systematic review and meta-analysis. *J Thorac Cardiovasc Surg* 2016;152:1279-1288.e3.
 8. Xie E, Liu J, Liu Y, et al. Association between platelet counts and morbidity and mortality after endovascular repair for type B aortic dissection. *Platelets* 2022;33:73-81.
 9. Wen D, Du X, Dong JZ, et al. Value of D-dimer and C reactive protein in predicting in-hospital death in acute aortic dissection. *Heart* 2013;99:1192-7.
 10. Zhu H, Zhang L, Liang T, et al. Elevated preoperative neutrophil-to-lymphocyte ratio predicts early adverse outcomes in uncomplicated type B aortic dissection undergoing TEVAR. *BMC Cardiovasc Disord* 2021;21:95.
 11. Zhao K, Zhu H, Ma J, et al. Peripheral Eosinophil Count Is Associated With the Prognosis of Patients With Type B Aortic Dissection Undergoing Endovascular Aortic Repair: A Retrospective Cohort Study. *J Am Heart Assoc* 2022;11:e027339.
 12. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 2006;444:840-6.
 13. Wang T, Li M, Zeng T, et al. Association Between Insulin Resistance and Cardiovascular Disease Risk Varies According to Glucose Tolerance Status: A Nationwide Prospective Cohort Study. *Diabetes Care* 2022;45:1863-72.
 14. Brito ADM, Hermsdorff HHM, Filgueiras MS, et al. Predictive capacity of triglyceride-glucose (TyG) index for insulin resistance and cardiometabolic risk in children and adolescents: a systematic review. *Crit Rev Food Sci Nutr* 2021;61:2783-92.
 15. Giannini C, Santoro N, Caprio S, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. *Diabetes Care* 2011;34:1869-74.
 16. Zhao J, Fan H, Wang T, et al. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. *Cardiovasc Diabetol* 2022;21:123.
 17. Che B, Zhong C, Zhang R, et al. Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data. *Cardiovasc Diabetol* 2023;22:34.
 18. MacGillivray TE, Gleason TG, Patel HJ, et al. The Society of Thoracic Surgeons/American Association for Thoracic Surgery clinical practice guidelines on the management of type B aortic dissection. *J Thorac Cardiovasc Surg* 2022;163:1231-49.
 19. Fritz J, Björge T, Nagel G, et al. The triglyceride-glucose index as a measure of insulin resistance and risk of obesity-related cancers. *Int J Epidemiol* 2020;49:193-204.
 20. James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. *Nat Rev Mol Cell Biol* 2021;22:751-71.
 21. Wu H, Ballantyne CM. Metabolic Inflammation and Insulin Resistance in Obesity. *Circ Res* 2020;126:1549-64.
 22. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. *Diabetes Care* 1996;19:278-86.
 23. Abbasi F, Reaven GM. Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides \times glucose versus triglyceride/high-density lipoprotein cholesterol. *Metabolism* 2011;60:1673-6.
 24. Salazar MR, Carbajal HA, Espeche WG, et al. Comparison of two surrogate estimates of insulin resistance to predict cardiovascular disease in apparently healthy individuals. *Nutr Metab Cardiovasc Dis* 2017;27:366-73.
 25. Shi W, Xing L, Jing L, et al. Value of triglyceride-glucose index for the estimation of ischemic stroke risk: Insights from a general population. *Nutr Metab Cardiovasc Dis* 2020;30:245-53.

26. Son BK, Sawaki D, Tomida S, et al. Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. *Nat Commun* 2015;6:6994.
27. Liu R, Lo L, Lay AJ, et al. ARHGAP18 Protects Against Thoracic Aortic Aneurysm Formation by Mitigating the Synthetic and Proinflammatory Smooth Muscle Cell Phenotype. *Circ Res* 2017;121:512-24.
28. Anzai A, Shimoda M, Endo J, et al. Adventitial CXCL1/G-CSF expression in response to acute aortic dissection triggers local neutrophil recruitment and activation leading to aortic rupture. *Circ Res* 2015;116:612-23.
29. Yang F, Liu J, Chen L, et al. Impact of Lymphocyte-Related Blood Parameters on Short- and Long-Term Outcomes of Patients Undergoing Thoracic Endovascular Aortic Repair. *Angiology* 2021;72:953-60.
30. Zhao Y, Hong X, Xie X, et al. Preoperative systemic inflammatory response index predicts long-term outcomes in type B aortic dissection after endovascular repair. *Front Immunol* 2022;13:992463.
31. Paccoud R, Saint-Laurent C, Piccolo E, et al. SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations. *Sci Transl Med* 2021;13:eabe2587.
32. Perry BI, Burgess S, Jones HJ, et al. The potential shared role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample mendelian randomization study. *PLoS Med* 2021;18:e1003455.
33. He F, Huang Y, Song Z, et al. Mitophagy-mediated adipose inflammation contributes to type 2 diabetes with hepatic insulin resistance. *J Exp Med* 2021;218:e20201416.
34. Koenen M, Hill MA, Cohen P, et al. Obesity, Adipose Tissue and Vascular Dysfunction. *Circ Res* 2021;128:951-68.
35. Adachi Y, Ueda K, Nomura S, et al. Being of perivascular adipose tissue regulates its inflammation and vascular remodeling. *Nat Commun* 2022;13:5117.
36. Lee SE, Sung JM, Andreini D, et al. Association Between Changes in Perivascular Adipose Tissue Density and Plaque Progression. *JACC Cardiovasc Imaging* 2022;15:1760-7.
37. Hoshino T, Mizuno T, Ishizuka K, et al. Triglyceride-glucose index as a prognostic marker after ischemic stroke or transient ischemic attack: a prospective observational study. *Cardiovasc Diabetol* 2022;21:264.
38. Huang R, Lin Y, Ye X, et al. Triglyceride-glucose index in the development of heart failure and left ventricular dysfunction: analysis of the ARIC study. *Eur J Prev Cardiol* 2022;29:1531-41.
39. Pan L, Bai P, Weng X, et al. Legumain Is an Endogenous Modulator of Integrin $\alpha\beta3$ Triggering Vascular Degeneration, Dissection, and Rupture. *Circulation* 2022;145:659-74.
40. Zheng H, Qiu Z, Chai T, et al. Insulin Resistance Promotes the Formation of Aortic Dissection by Inducing the Phenotypic Switch of Vascular Smooth Muscle Cells. *Front Cardiovasc Med* 2021;8:732122.
41. Yang X, Xu C, Yao F, et al. Targeting endothelial tight junctions to predict and protect thoracic aortic aneurysm and dissection. *Eur Heart J* 2023;44:1248-61.
42. Artunc F, Schleicher E, Weigert C, et al. The impact of insulin resistance on the kidney and vasculature. *Nat Rev Nephrol* 2016;12:721-37.
43. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. *Diabetes Metab Res Rev* 2006;22:423-36.
44. Tripolino C, Irace C, Scavelli FB, et al. Triglyceride glucose index and common carotid wall shear stress. *J Investig Med* 2014;62:340-4.
45. Liu C, Dhindsa D, Almuwaqqat Z, et al. Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. *JAMA Cardiol* 2022;7:672-80.
46. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. *Eur Heart J* 2017;38:2478-86.

Cite this article as: Zhao K, Niu J, Zhu H, Zhao R, Sun Y, Li S, Jing Z, Zhou J. Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio predict the prognosis in patients with type B aortic dissection receiving thoracic endovascular aortic repair. *J Thorac Dis* 2024;16(3):1971-1983. doi: 10.21037/jtd-23-1411

Table S1 Univariate and multivariate Cox proportional hazard modeling analysis for 1-year all-cause mortality (continuous TG/HDL-c)

Variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
Age	1.03 (1.01, 1.05)	0.009	1.02 (0.99, 1.05)	0.188
Male	3.46 (1.07, 11.16)	0.038	3.34 (0.98, 11.33)	0.053
BMI	0.94 (0.84, 1.05)	0.265	–	–
Smoking	0.98 (0.55, 1.76)	0.95	–	–
SBP at admission	1.01 (0.99, 1.02)	0.250	–	–
DBP at admission	0.99 (0.97, 1.02)	0.688	–	–
Hypertension	1.32 (0.64, 2.73)	0.456	–	–
CAD	1.69 (0.67, 4.27)	0.270	–	–
Diabetes mellitus	2.72 (1.35, 5.49)	0.005	1.31 (0.51, 3.36)	0.571
Stroke	3.48 (1.62, 7.47)	0.001	2.64 (1.09, 6.41)	0.031
COPD	0.79 (0.31, 2.01)	0.624	–	–
CKD	2.67 (1.19, 5.97)	0.017	2.71 (1.08, 6.82)	0.034
Timing of operation				
Acute	Reference	–	–	–
Sub-acute	0.97 (0.47, 2.03)	0.939	–	–
Chronic	1.00 (0.37, 2.66)	0.996	–	–
Pericardial effusion	3.3 (1.59, 6.85)	0.001	0.69 (1.55, 8.80)	0.003
Pleural effusion	1.12 (0.61, 2.05)	0.724	–	–
Glucose	1.01 (1.00, 1.01)	0.003	1.01 (1.00, 1.01)	0.115
Uric acid	1.00 (1.00, 1.00)	0.928	–	–
TG/HDL-c	1.07 (1.01, 1.13)	0.030	1.07 (1.00, 1.15)	0.041

TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.

Table S2 Univariate and multivariate Cox proportional hazard modeling analysis for 1-year all-cause mortality (TG/HDL-c ratio group)

Variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
Age	1.03 (1.01, 1.05)	0.009	1.03 (1.01, 1.06)	0.007
Male	3.46 (1.07, 11.16)	0.038	5.27 (1.59, 17.44)	0.006
BMI	0.94 (0.84, 1.05)	0.265	–	–
Smoking	0.98 (0.55, 1.76)	0.95	–	–
SBP at admission	1.01 (0.99, 1.02)	0.250	–	–
DBP at admission	0.99 (0.97, 1.02)	0.688	–	–
Hypertension	1.32 (0.64, 2.73)	0.456	–	–
CAD	1.69 (0.67, 4.27)	0.270	–	–
Diabetes mellitus	2.72 (1.35, 5.49)	0.005	1.15 (0.51, 2.58)	0.7315
Stroke	3.48 (1.62, 7.47)	0.001	3.06 (1.37, 6.86)	0.006
COPD	0.79 (0.31, 2.01)	0.624	–	–
CKD	2.67 (1.19, 5.97)	0.017	3.08 (1.32, 7.17)	0.009
Timing of operation				
Acute	Reference	–	–	–
Sub-acute	0.97 (0.47, 2.03)	0.939	–	–
Chronic	1.00 (0.37, 2.66)	0.996	–	–
Pericardial effusion	3.3 (1.59, 6.85)	0.001	3.01 (1.42, 6.36)	0.004
Pleural effusion	1.12 (0.61, 2.05)	0.724	–	–
Glucose	1.01 (1.00, 1.01)	0.003	1.03 (1.00, 1.01)	0.007
Uric acid	1.00 (1.00, 1.00)	0.928	–	–
TG/HDL-c ratio groups				
Quintile 4	Reference	–	Reference	–
Quintile 1	3.42 (1.12, 10.50)	0.031	4.67 (1.46, 14.94)	0.001
Quintile 2	1.47 (0.41, 5.21)	0.551	1.88 (0.52, 6.82)	0.337
Quintile 3	1.94 (0.58, 6.44)	0.280	2.21 (0.65, 7.57)	0.206
Quintile 5	3.55 (1.18, 10.69)	0.024	4.84 (1.55, 15.13)	0.007

Quintile 1: TG/HDL-c ratio <1.44. Quintile 2: 1.44 ≤ TG/HDL-c ratio <2.09. Quintile 3: 2.09 ≤ TG/HDL-c ratio <2.97. Quintile 4: 2.97 ≤ TG/HDL-c ratio <4.11. Quintile 5: TG/HDL-c ratio ≥4.11. TG/HDL-c, triglyceride to high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease.

Table S3 Univariate and multivariate Cox proportional hazard modeling analysis for 1-year MACCEs (continuous TyG index)

Variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
Age	1.03 (1.00, 1.05)	0.009	1.03 (1.00, 1.06)	0.012
Male	3.46 (1.07, 11.16)	0.038	–	–
BMI	0.94 (0.84, 1.05)	0.265	–	–
Smoking	0.98 (0.55, 1.76)	0.950	–	–
SBP at admission	1.01 (0.99, 1.01)	0.892	–	–
DBP at admission	0.99 (0.97, 1.01)	0.29	–	–
Hypertension	1.32 (0.56, 1.47)	0.698	–	–
CAD	1.69 (0.44, 2.32)	0.98	–	–
Diabetes	2.72 (0.76, 2.68)	0.272	–	–
Stroke	3.48 (1.41, 4.78)	0.002	2.60 (1.19, 5.68)	0.016
COPD	0.79 (0.38, 1.50)	0.418	–	–
CKD	2.67 (0.99, 3.69)	0.054	2.46 (1.08, 5.61)	0.033
Timing of operation				
Acute	Reference	–	–	–
Sub-acute	0.97 (0.63, 1.75)	0.863	–	–
Chronic	1.00 (0.77, 2.70)	0.255	–	–
Pericardial effusion	3.30 (1.28, 4.17)	0.005	3.43 (1.62, 7.25)	0.001
Pleural effusion	1.12 (0.63, 1.54)	0.948	–	–
WBC	1.05 (0.96, 1.08)	0.565	–	–
Creatinine	1.00 (1.00, 1.00)	0.100	–	–
Platelet	0.99 (1.00, 1.00)	0.435	–	–
Uric acid	1.00 (1.00, 1.00)	0.910	–	–
TyG	1.32 (1.18, 2.22)	0.003	1.04 (0.58, 1.85)	0.897

MACCEs, major adverse cardiovascular and cerebrovascular events; TyG, triglyceride-glucose; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; WBC, white blood cell.

Table S4 Univariate and multivariate Cox proportional hazard modeling analysis for 1-year MACCEs

Variables	Univariate analysis	
	HR (95% CI)	P value
Age	1.03 (1.00, 1.07)	0.0644
Male	2.19 (0.51, 9.44)	0.2932
BMI	0.99 (0.86, 1.15)	0.9314
Smoking	0.98 (0.41, 2.37)	0.968
SBP at admission	0.99 (0.97, 1.02)	0.615
DBP at admission	0.98 (0.94, 1.02)	0.4136
Hypertension	1.26 (0.42, 3.77)	0.6806
CAD	4.82 (1.75, 13.27)	0.0023
Diabetes mellitus	4.30 (1.65, 11.20)	0.0028
Stroke	7.07 (2.71, 18.42)	<0.0001
COPD	0 (0.00, inf)	0.9972
CKD	3.70 (1.24, 11.07)	0.0193
Timing of operation		
Acute	Reference	
Sub-acute	1.60 (0.62, 4.15)	0.3324
Chronic	1.46 (0.39, 5.38)	0.5723
Pericardial effusion	3.37 (1.13, 10.08)	0.0299
Pleural effusion	1.12 (0.45, 2.81)	0.8059
Uric acid	1.00 (1.00, 1.00)	0.9566
Continuous TG/HDL-c	1.05 (0.95, 1.17)	0.3408
Continuous TyG index	1.37 (0.69, 2.72)	0.3654
TG/HDL-c ratio groups		
Quintile 4	4.67 (1.46, 14.94)	0.001
Quintile 1	1.88 (0.52, 6.82)	0.337
Quintile 2	2.21 (0.65, 7.57)	0.206
Quintile 3	4.84 (1.55, 15.13)	0.007
Quintile 5	4.67 (1.46, 14.94)	0.001

Quintile 1: TG/HDL-c ratio <1.44. Quintile 2: $1.44 \leq$ TG/HDL-c ratio <2.09. Quintile 3: $2.09 \leq$ TG/HDL-c ratio <2.97. Quintile 4: $2.97 \leq$ TG/HDL-c ratio <4.11. Quintile 5: TG/HDL-c ratio \geq 4.11. MACCEs, major adverse cardiovascular and cerebrovascular events; HR, hazard ratio; CI, confidence interval; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; inf, infinity; CKD, chronic kidney disease; TG/HDL-c, triglyceride to high-density lipoprotein cholesterol.

Table S5 Results for the tests of equality of group means to test for difference in the means across ARAEs groups once redundant variables have been removed

Variables	Wilks' lambda	F	df1	df2	Sig.	Rank
Hypertension	0.986	8.34	1	935	0.004	1
TyG index	0.987	7.538	1	935	0.006	2
Uric acid	0.988	6.862	1	935	0.009	3
WBC	0.991	5.07	1	935	0.025	4
Pericardial effusion	0.993	4	1	935	0.046	5
DBP	0.995	2.795	1	935	0.095	6
HDL-C	0.996	2.343	1	935	0.126	7
Diabetes mellitus	0.997	1.976	1	935	0.16	8
CAD	0.997	1.807	1	935	0.179	9
Pleura effusion	0.997	1.707	1	935	0.192	10
Male	0.998	1.239	1	935	0.266	11
Timing of operation	0.999	0.52	1	935	0.471	12
Platelet	0.999	0.519	1	935	0.472	13
COPD	0.999	0.344	1	935	0.558	14
BMI	0.999	0.295	1	935	0.587	15
Stroke	1	0.181	1	935	0.671	16
LDL-C	1	0.123	1	935	0.726	17
Smoking	1	0.12	1	935	0.73	18
CKD	1	0.039	1	935	0.844	19
Creatinine	1	0.015	1	935	0.903	20
SBP	1	0.014	1	935	0.907	21
Age	1	0.004	1	935	0.952	22

ARAEs, aortic-related adverse events; df, degree of freedom; Sig., significance; TyG, triglyceride-glucose; WBC, white blood cell; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; CKD, chronic kidney disease; SBP, systolic blood pressure.

Table S6 Canonical discriminant analysis efficiency parameters to determine the significance of each canonical discriminant function

Test of function	Wilks' lambda	Chi-square	df	Sig.
1 through 8	0.963	21.915	1	0.000

df, degree of freedom; Sig., significance.